Half of breast cancer patients discontinue tamoxifen and any endocrine treatment before the end of the recommended treatment period of 5 years: A population-based analysis
Myrthe P.P. Van Herk-Sukel, Lonneke V. Van De Poll-Franse, Adri C. Voogd, Grard A.P. Nieuwenhuijzen, Jan Willem W. Coebergh, Ron M.C. Herings
Research output: Contribution to journal › Article › Academic › peer-review
Fingerprint
Dive into the research topics of 'Half of breast cancer patients discontinue tamoxifen and any endocrine treatment before the end of the recommended treatment period of 5 years: A population-based analysis'. Together they form a unique fingerprint.